To the Editor: We previously reported detection of double resistance to oseltamivir and amantadine of influenza virus A (H1N1) in Hong Kong during the first half of 2008 (1). Three different strains of A/Hong Kong/2652/2006-like (clade 2C) viruses that carried the S31N mutation in the matrix (M2) gene associated with amantadine resistance acquired a neuraminidase (NA) gene with CAT→TAT change at position 274 through either reassortment with an oseltamivir-resistant A/Brisbane/59/2007-like (clade 2B) virus or spontaneous H274Y mutation in the NA gene. A clade 2C strain resistant to both oseltamivir and amantadine also was detected in Cambodia in 2007 (2).

From July 2008 through December 2008, we continued to monitor antiviral susceptibility of all influenza A (H1N1) viruses in our laboratory, using previously described methods (1). Resistance to oseltamivir increased from 16.9% in July to 97.8% in December (Table). Sequencing of the hemagglutinin (HA) gene showed that, beginning in October, A/Brisbane/59/2007-like clade 2B virus had overtaken A/Hong Kong/2652/2006-like clade 2C virus to become the predominating circulating influenza A virus (H1N1) in Hong Kong. Of 916 isolates, 6 (0.7%), isolated from July through September 2008, were resistant to both amantadine and oseltamivir. Genetic analysis showed that 5 were similar to those we described previously, 4 were A/Hong Kong/2652/2006-like clade 2C viruses with spontaneous H274Y mutation in the NA gene, and 1 was a clade 2C virus but acquired a clade 2B NA gene carrying the H274Y mutation. The sixth double-resistant virus was an A/Brisbane/59/2007-like clade 2B virus with a spontaneous S31N mutation in the M2 gene. No epidemiologic link was detectable between these viruses. From October through December 2008, no double-resistant viruses were detected.

From January through June 2009, A/Brisbane/59/2007-like clade 2B virus continued to be the predominating strain. Of the total 1,537 influenza virus A (H1N1) isolates tested during the period, 1,509 (98.2%) were resistant to oseltamivir. Of the 1,509 oseltamivir-resistant isolates tested from April through June 2009, 50 (3.3%) also were resistant to amantadine (Table). Nucleotide sequencing of the HA, NA, and M2 genes was performed on all 50 oseltamivir- and amantadine-resistant viruses. All were A/Brisbane/59/2007-like clade 2B viruses that had acquired an M2 gene carrying the S31N mutation by reassortment with an amantadine-resistant A/Hong Kong/2652/2006-like clade 2C virus. Nucleotide sequencing of the other 5 internal genes (nonstructural, nucleoprotein, polymerase acidic, polymerase basic 1, and polymerase basic 2 proteins) was performed on 2 double-resistant strains isolated in April and on 3 isolated in June. Sequence comparison showed that 1 virus in April, in addition to acquiring an M2 gene, acquired a nonstructural protein gene from an A/Hong Kong/2652/2006-like clade 2C virus. All the viruses were susceptible to zanamivir and were not associated with unusual severity of disease.

Along with pandemic (H1N1) 2009, seasonal influenza viruses continue to circulate in Hong Kong (3). An alarming proportion of the circulating seasonal influenza A virus

Osel tami v ir- and Amantadine-Resistant Influenza Virus A (H1N1)


Address for correspondence: Stuart C. Clarke, Molecular Microbiology and Infection, Sir Henry Wellcome Laboratories, South Block, Southampton General Hospital, Southampton SO16 6YD, UK; email: s.c.clarke@southampton.ac.uk
(H1N1) became resistant to both oseltamivir and amantadine in a short span of 1 month. Oseltamivir-resistant A/Brisbane/59/2007-like clade 2B virus that had reassorted with A/Hong Kong/2626/2006-like clade 2C virus had apparently spread in the community and to other regions of the world. The possibility of reassortment with pandemic (H1N1) 2009 virus is a major concern. Resistance to oseltamivir of pandemic (H1N1) 2009 virus will compromise its use in treatment and render the billion-dose stockpile useless. Although the recently detected oseltamivir-resistant pandemic (H1N1) 2009 virus in Hong Kong was not a reassortant virus (4, 5), we will continue to closely monitor antiviral drug resistance among circulating viruses, including pandemic (H1N1) 2009 virus and seasonal influenza virus A (H1N1), as well as influenza A (H3N2) viruses, to track how antiviral resistance evolves.


Author affiliation: Department of Health, Hong Kong, People’s Republic of China

DOI: 10.3201/eid1601.091304

References


Address for correspondence: Wilina W.L. Lim, Public Health Laboratory Centre, 382 Nam Cheong St, Shek Kip Mei, Kowloon, Hong Kong Special Administrative Region, People’s Republic of China; email: wllim@pacific.net.hk

---

**Pandemic (H1N1) 2009 Reinfecion, Chile**

To the Editor: Since March 2009, influenza A pandemic (H1N1) 2009 has spread worldwide (1), and in South America, Chile was 1 of the countries most affected by the pandemic, with 21.4 cases among every 1,000 persons. Treatment guidelines in Chile recommended antiviral drug treatment with oseltamivir or zanamivir for 5 days for all patients with confirmed or suspected virus subtype H1N1 infection (2). In persons with seasonal influenza, specific antibody responses reach peak titers by 4 weeks after infection and confer protection against the infecting strain and closely related strains (3). Reinfection is rarely seen in nonpandemic influenza A. We report on 3 patients with confirmed influenza A pandemic (H1N1) 2009 reinfection after successful treatment with oseltamivir.

Patient 1, a healthy 14-year-old girl, had fever, sore throat, and nasal congestion on clinical examination. Pandemic (H1N1) 2009 infection was diagnosed by viral culture and confirmed by PCR specific for subtype H1N1 (LightMix Kit Influenza H1; TIB MOLBIOL, Berlin, Germany, for Roche Diagnostic, Indianapolis, IN, Light Cycler 2.0 instrument). The patient received oseltamivir, and symptoms resolved 48 hours after treatment. Twenty days later, fever, muscle aches, and vomiting developed in the patient. Influenza A virus was isolated by viral culture. The patient received a preliminary diagnosis of seasonal influenza and was treated with amantadine. She recovered from the infection before PCR results confirmed it was caused by pandemic (H1N1) 2009 virus.

Patient 2, a 62-year-old woman, experienced a high fever, cough, and nasal congestion during a prolonged hospitalization for bowel resection after intestinal ischemia. Pandemic (H1N1) 2009 was confirmed by PCR and viral culture. Oseltamivir was administered 5 days after the onset of symptoms, and the symptoms resolved within the following 5 days. The patient had a new episode of fever, productive cough, and bronchial obstruction 2 weeks later while still hospitalized. Culture results were positive for influenza, and PCR results were positive for pandemic (H1N1) 2009. The patient was again treated with oseltamivir, and PCR results were negative for influenza after 48 hours of antiviral treatment.

Patient 3, a previously healthy 38-year-old man, underwent mitral and aortic valve replacement while hospitalized for acute mitral and aortic endocarditis due to *Staphylococcus aureus*. Eleven days after surgery, he had a sore throat, nasal congestion, cough, and low-grade fever. PCR test results were positive for pandemic (H1N1) 2009. The patient received oseltamivir, and respiratory symptoms resolved within 5 days. He was discharged from the hospital but was